Introduction {#Sec1}
============

Ezetimibe inhibits absorption of cholesterol at the brush border of the small intestine via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1)^[@CR1]^. This leads to a decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and an increased clearance of cholesterol from the blood and studies have shown a reduction in LDL-cholesterol (LDL-C) by 17% when used alone^[@CR2]^ and a reduction of 14--25% in combination with statins^[@CR3]^. The IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) in 18144 subjects with recent acute coronary syndrome showed that ezetimibe 10 mg added to simvastatin 40 mg daily reduced LDL-C by 16% with a 6% reduction in the risk of the primary cardiovascular outcome^[@CR4]^.

Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL)-like particle with proatherogenic, prothrombotic and proinflammatory properties that make it a significant contributor to atherothrombotic events^[@CR5]--[@CR10]^. Lp(a) has been suggested to be an independent risk factor for cardiovascular disease with an increased odds ratio of 1.6^[@CR11]^; however, a large meta-analysis of 36 prospective studies showed the risk ratio was 1.13^[@CR12]^. Lp(a) is associated with acute coronary syndrome^[@CR13]^ and increased levels are found commonly in patients with premature coronary heart disease^[@CR14]^. Therefore, therapeutic approaches capable of reducing elevated plasma Lp(a) concentrations may be important.

Kinetic studies have concluded that Lp(a) levels are mainly regulated by differences in biosynthesis, and biosynthetic changes have been associated to the Lp(a) lowering activity of anacetrapib^[@CR15]^. Recent reports have also indicated the role of plasminogen receptor KT in Lp(a) cell internalization, which is followed by recycling of the apo(a) component^[@CR16]^. Additional to these mechanisms, there is evidence showing that Lp(a) serves as an acute-phase reactant and its biosynthesis is augmented by inflammation^[@CR17]--[@CR19]^. Ezetimibe is known to possess anti-inflammatory activity and may therefore affect Lp(a) production^[@CR20],[@CR23]^. The involvement of the LDL receptor (LDLR) in the catabolism and clearance of plasma Lp(a) has also been discussed^[@CR24],[@CR25]^. On the other hand, ezetimibe has been reported to potentiate the stimulating activity of statins on *LDLR* gene expression^[@CR26]^. Given these lines of evidence, it might be plausible that the benefits of ezetimibe in improving outcomes, such as that observed in the IMPROVE-IT study, may in part be due to a decrease in Lp(a) levels and this meta-analysis of all randomized controlled trials was undertaken to determine if ezetimibe therapy does decrease Lp(a) levels.

Methods {#Sec2}
=======

Search Strategy {#Sec3}
---------------

This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement^[@CR27]^. PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched using the following search terms within titles and abstracts (also in combination with MESH terms): (ezetimibe) AND (lipoprotein(a) OR "lipoprotein (a)" OR Lp(a) OR "Lp (a)"). Sensitivity of the search strategy was increased by using the wild-card term "\*". The search was limited to articles published in English language. The literature was searched from inception to February 26, 2018.

Study Selection {#Sec4}
---------------

Original studies were included if they met the following inclusion criteria: (i) being a randomized placebo-controlled trial with either parallel or cross-over design, (ii) investigating the impact of ezetimbe *vs*. placebo (or ezetimibe plus a statin *vs*. statin alone) on plasma/serum concentrations of Lp(a), and, (iii) presentation of sufficient information on Lp(a) concentrations at baseline and at the end of follow-up in each group or providing the net change values. Exclusion criteria were: (i) non-randomized controlled trials, (ii) lack of a control group for ezetimibe treatment, (iii) observational studies with case-control, cross-sectional or cohort design, and (iv) lack of sufficient information on baseline or follow-up Lp(a) concentrations.

Data extraction {#Sec5}
---------------

Eligible studies were reviewed and the following data were abstracted: (1) first author's name; (2) year of publication; (3) country were the study was performed; (4) study design; (5) number of participants in the ezetimibe and control groups; (6) comedications including statins; (7) dose of ezetimibe; (8) treatment duration; (9) age, gender and body mass index (BMI) of study participants; (9) method of Lp(a) assay; and (10) data regarding baseline and follow-up plasma concentrations of Lp(a).

Quality assessment {#Sec6}
------------------

Included studies were systematically evaluated for the risk of bias according to the Cochrane criteria^[@CR28]^, and as previously described, that included the assessment of each study for: adequacy of sequence generation, allocation concealment, blinding, addressing of dropouts (incomplete outcome data) and selective outcome reporting. According to the recommendations of the Cochrane Handbook, a judgment of "yes" indicated low risk of bias, while "no" indicated high risk of bias. Labeling an item as "unclear" indicated an unclear or unknown risk of bias.

Quantitative Data Synthesis {#Sec7}
---------------------------

Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ)^[@CR29]^ was used to undertake the meta-analysis. Effect size was calculated as: (measure at the end of follow-up in the treatment group -- measure at baseline in the treatment group) -- (measure at the end of follow-up in the control group -- measure at baseline in the control group). A random-effects model (using DerSimonian-Laird method) and the generic inverse variance weighting method were used to compensate for the heterogeneity of studies in terms of study design, treatment duration, and the characteristics of populations being studied^[@CR30]^. All values were collated as percentage changes. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root \[(SD~pre-treatment~)^2^ + (SD~post-treatment~)^2^ − (2 R × SD~pre-treatment~ × SD~post-treatment~)\], assuming a correlation coefficient (R) = 0.5^[@CR31]--[@CR33]^. Heterogeneity index was assessed using I^2^ index and Cochrane Q test. If the outcome measures were reported in median and range (or 95% confidence interval), mean and standard SD values were estimated using the method described by Wan *et al*.^[@CR34]^. Where standard error of the mean (SEM) was only reported, SD was estimated using the following formula: SD = SEM × sqrt (*n*), where *n* is the number of subjects. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). If the outcome measures were reported in median and range (or 95% CI), mean and SD values were estimated using the method described by Wan *et al*.^[@CR34]^. In order to evaluate the influence of each study on the overall effect size, a sensitivity analysis was conducted using the leave-one-out method (i.e., removing one study each time and repeating the analysis)^[@CR35]--[@CR38]^.

Meta-regression {#Sec8}
---------------

As potential confounder of treatment response, baseline plasma Lp(a) levels were entered into a random-effects meta-regression model to explore their association with the estimated effect size on plasma Lp(a) concentrations^[@CR37]^.

Publication bias {#Sec9}
----------------

Evaluation of funnel plot, Begg's rank correlation and Egger's weighted regression tests were employed to assess the presence of publication bias in the meta-analysis^[@CR38]^. When there was an evidence of funnel plot asymmetry, potentially missing studies were imputed using the "trim and fill" method^[@CR39]^.

Results {#Sec10}
=======

Characteristics of included studies {#Sec11}
-----------------------------------

A total of 408 clinical trials were identified of which 390 did not meet the inclusion criteria and were excluded. Eighteen full-text articles were carefully reviewed for eligibility from which 8 studies were excluded due to the lack of control group (n = 3), no ezetimibe arm (n = 2), lp(a) concentrations were not measured (n = 2), and not presenting numerical values (n = 1). After this assessment, 10 clinical trials were selected and included in this systematic review and meta-analysis. Flow chart that detailing the studies identified, screened, those that were eligible and those that were included into the meta-analysis is shown in Fig. [1](#Fig1){ref-type="fig"}.Figure 1Flow chart that detailing the studies identified, screened, those that were eligible and those that were included into the meta-analysis.

Data were pooled from 10 clinical trials comprising a total of 5188 subjects, including 3020 and 2168 participants in the ezetimibe therapy and control arms (individuals of the cross-over trials were considered in treatment and control groups), respectively. Selected studies were published between 2002 and 2012. The range of intervention periods was from 5 weeks^[@CR40]^ to 12 weeks^[@CR3],[@CR41]--[@CR47]^. Study designs of included trials were parallel^[@CR3],[@CR41]--[@CR48]^ and cross-over group^[@CR40]^. Evaluated studies enrolled subjects with primary hypercholesterolemia^[@CR3],[@CR41]--[@CR48]^ and severe hypercholesterolemia^[@CR40]^. Characteristics of the included clinical trials are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic characteristics of the included studies.AuthorStudy designTarget PopulationTreatment durationnStudy groupsAge, yearsFemale (n, %)Baseline BMI, (kg/m^2^)Baseline Total cholesterol (mg/dl)Baseline LDL cholesterol (mg/dl)Baseline HDL cholesterol (mg/dl)Baseline Triglycerides (mg/dl)Baseline lipoprotein(a) (mg/dl)Ballantyne *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks60 65 248 255Placebo Ezetimibe 10 mg/day Atorvastatin 10-80 mg/day Ezetimibe 10 mg/day + atorvastatin 10-80 mg/day56.9 ± 12.1 56.7 ± 11.7 57.8 ± 11.7 58.7 ± 11.431 (52) 36 (55) 153 (62) 148 (58)ND\
ND\
ND\
ND261.8 ± 27.1 259.1 ± 28.2 268.8 ± 23.6 267.2 ± 23.9177.9 ± 20.9 175.2 ± 21.7 179.8 ± 23.6 179.8 ± 23.950.3 ± 11.6 50.7 ± 12.0 53.8 ± 12.5 50.7 ± 12.7141.7\* 141.7\*\
150.6\*\
168.3\*ND\
ND\
ND\
NDDavidson *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks70 61 263 274Placebo Ezetimibe 10 mg/day Simvastatin 10--80 mg/day Ezetimibe 10 mg/day + simvastatin 10--80 mg/day58.8 (25--84)\*\* 60.3 (35--84)\*\* 56.4 (25--87)\*\* 57.6 (27--83)\*\*39 (56) 37 (61) 153 (58) 148 (54)ND\
ND\
ND\
NDND\
ND\
ND\
ND177.4 ± 21.7 181.3 ± 23.0 178.5 ± 20.0 176.3 ± 19.952.3 ± 12.1 51.0 ± 11.5 51.0 ± 10.9 50.4 ± 12.2170.9 ± 68.5 190.3 ± 68.2 168.7 ± 59.8 178.8 ± 65.130.1^†^\
34.7^†^\
33.0^†^\
30.8^†^Dujovne *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks226 666Placebo Ezetimibe 10 mg/day58.1 (30--85)\*\*\
57.9 (18--85)\*\*124 (55)\
334 (50)28.4 (19.4--49.5)\*\* 28.6 (17.5--47)\*\*254.5^†^ 252.8^†^168.0^†^ 167.8^†^52.2^†^ 52.1^†^174.8^†^ 169.0^†^27.5^†^\
33.5^†^Geiss *et al*.^[@CR43]^Randomized, double-blind, placebo-controlled, cross-overSevere hypercholeste-rolemia5 weeks20 20 20Overall Placebo Ezetimibe 10 mg/day56 ± 910 (50)27.5 ± 4.0394.4^†^317.5^†^46.4^†^158.5^†^ND\
32 ± 20 33 ± 27Goldberg *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks93 92 349 353Placebo Ezetimibe 10 mg/day Simvastatin 10--80 mg/day Ezetimibe 10 mg/day + simvastatin 10--80 mg/dayND\
ND\
ND\
ND55 (59) 57 (62) 177 (51) 184 (52)ND\
ND\
ND\
ND258 ± 32 262 ± 30 259 ± 30 260 ± 30174 ± 28 176 ± 26 175 ± 25 175 ± 2750 ± 12 51 ± 13 49 ± 12 51 ± 13162 ± 83^†^ 163 ± 104^†^ 167 ± 89^†^ 169 ± 93^†^37 ± 38 35 ± 30 29 ± 27 31 ± 31Kerzner *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks64 72 220 192Placebo Ezetimibe 10 mg/day Lovastatin 10--40 mg/day Ezetimibe 10 mg/day + lovastatin 10--40 mg/day58 ± 12 55 ± 11 56 ± 12 57 ± 1140 (63) 41 (57) 132 (60) 106 (55)ND\
ND\
ND\
ND266 ± 24 264 ± 25 265 ± 29 262 ± 27178 ± 24 178 ± 16 178 ± 14 176 ± 1354 ± 16 51 ± 8 51 ± 14 50 ± 13168 ± 64 170 ± 59 178 ± 59 172 ± 5534 ± 32 35 ± 33 35 ± 29 35 ± 27Knopp *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks205 622Placebo Ezetimibe 10 mg/day57.6 (24--79)\*\*\
58.3 (20--86)\*\*110 (54) 320 (51)29.6 (19.4--45.7)\*\* 29.1 (17.8--49.6)\*\*248.6^†^ 249.0^†^164.3^†^ 165.1^†^51.0^†^ 52.2^†^170.9^†^ 163.0^†^33.6^†^\
30.8^†^Melani *et al*.^[@CR43]^Randomized, double-blind, placebo-controlledPrimary hypercholeste-rolemia12 weeks65 64 205 204Placebo Ezetimibe 10 mg/day Pravastatin 10--40 mg/day Ezetimibe 10 mg/day + pravastatin 10--40 mg/day53.4 (32--76)\*\*\
52.0 (26--75)\*\*\
55.1 (23--84)\*\*\
56.9 (20--86)\*\*34 (52) 41 (64) 104 (51) 121 (59)ND\
ND\
ND\
NDND\
ND\
ND\
ND177.9 ± 19.3 177.9 ± 23.2 177.9 ± 23.2 177.9 ± 19.350.3 ± 11.6 50.3 ± 11.6 50.3 ± 11.6 50.3 ± 11.6159.4 ± 62.0 177.1 ± 62.0 177.1 ± 62.0 177.1 ± 62.033.6^†^\
30.8^†^\
30.8^†^\
30.8^†^Moutzouri *et al*.^[@CR43]^Randomized, open-label, controlledPrimary hypercholeste-rolemia12 weeks30 30Simvastatin 40 mg/day Ezetimibe 10 mg/day + simvastatin 40 mg/day56.9 ± 13 56.9 ± 1114 (46) 18 (60)29 ± 5 29 ± 5260 ± 45 271 ± 35174 ± 41 179 ± 2660 ± 12 61 ± 14112 (58--129)‡ 119 (67--142) ‡7.5 (2.3--21.3)‡ 4.7 (2.4--54.1)‡Saougos *et al*.^[@CR43]^Open-label, controlledPrimary hypercholeste-rolemia8 weeks50 50Ezetimibe 10 mg/day Rosuvastatin 10 mg/day48.1 ± 19.5 54.6 ± 14.627 (54) 31 (62)24.5 ± 7.9 25.8 ± 4.2263 ± 34 297 ± 50170 ± 30 208 ± 4261 ± 15 58 ± 11141 ± 44 141 ± 534.2 (2.0--6.1)‡ 4.0 (2.0--7.4)‡Values are expressed as mean ± SD.\*Median.\*\*Mean (IQR).^†^Mean.^‡^Median (IQR).Abbreviations: ND, no data; BMI, body mass index; IQR, interquartile range.Demographic characteristics of the studies that were included in this meta-analysis.

Lp(a) assay methods {#Sec12}
-------------------

The majority of the studies included in the meta-analysis quantified Lp(a) levels by competitive enzyme-linked immunosorbent assay^[@CR3],[@CR41]--[@CR46],[@CR48]^, while other trials determined Lp(a) levels by a nephelometric assay (Dade Behring)^[@CR40],[@CR47]^.

Risk of bias in the included studies {#Sec13}
------------------------------------

Several studies showed low risk of bias regarding random sequence generation, only one trial had high risk of bias for this parameter^[@CR48]^. Most of the included studies had a lack of information about the allocation concealment, and a high risk of bias was found in one trial^[@CR48]^. Several studies presented insufficient information on the blinding process of the participants, study personnel and the outcome assessors, and two trials showed high risk of bias^[@CR47],[@CR48]^. Almost all of the assessed studies showed that there was a low risk of bias for incomplete outcome data, only one trial exhibited limited information^[@CR41]^. Finally, all selected studies presented low risk of bias regarding selective outcome reporting. Cochrane guidelines applied to the assessment of quality of bias in the studies that were included in the meta-analysis are shown in Table [2](#Tab2){ref-type="table"}.Table 2Quality of bias assessment of the included studies according to the Cochrane guidelines.StudySequence generationAllocation concealmentBlinding of participants, personnel and outcome assessorsIncomplete outcome dataSelective outcome reportingOther sources of biasBallantyne *et al*.^[@CR43]^UUUULUDavidson *et al*.^[@CR43]^LUULLUDojovne *et al*.^[@CR43]^LLULLUGeiss *et al*.^[@CR43]^UUULLUGoldberg *et al*.^[@CR43]^LUULLUKerzner *et al*.^[@CR43]^UUULLUKnopp *et al*.^[@CR43]^LUULLUMelani *et al*.^[@CR43]^LUULLUMoutzouri *et al*.^[@CR43]^LUHLLUSaougos *et al*.^[@CR43]^HHHLLUL, low risk of bias; H, high risk of bias; U, unclear risk of bias.Cochrane guidelines applied to the assessment of quality of bias in the studies that were included in the meta-analysis.

Effect of Ezetimibe on plasma Lp(a) concentrations {#Sec14}
--------------------------------------------------

Overall, 10 studies comprising 15 treatment arms were included in the meta-analysis. Meta-analysis did not suggest a significant change in plasma Lp(a) concentrations following treatment with ezetimibe (WMD: −2.59%, 95% CI: −8.26, 3.08, *p* = 0.370; I^2^ = 88.71%, *p*~(Q)~ \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}). The effect size was robust in sensitivity analysis (Fig. [2](#Fig2){ref-type="fig"}) and the effect size remained significant or marginally significant after omission of each single study from the meta-analysis.Figure 2Weighted mean difference and 95% confidence intervals for the impact of ezetimibe on plasma Lp(a) concentrations displayed as a Forest plot. The results of leave-one-out sensitivity analysis is shown in the lower panel.

In the subgroup analysis, no significant alteration in plasma Lp(a) levels was observed either in trials assessing the impact of monotherapy with ezetimibe versus placebo (WMD: −4.64%, 95% CI: −11.53, 2.25, *p* = 0.187; I^2^ = 65.38%, *p*~(Q)~ = 0.005) or in trials evaluating the impact of adding ezetimibe to a statin versus statin therapy alone (WMD: −1.04%, 95% CI: −6.34, 4.26, *p* = 0.700; I^2^ = 58.51%, *p*~(Q)~ = 0.025) (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Weighted mean difference and 95% confidence intervals for the impact of ezetimibe on plasma Lp(a) concentrations in subgroups of trials administering ezetimibe as monotherapy or in combination with statins displayed as a Forest plot. The results of leave-one-out sensitivity analysis is shown in the lower panel.

Meta-regression {#Sec15}
---------------

To assess the impact of baseline Lp(a) concentrations on the effect of ezetimibe on plasma Lp(a) levels, a random-effects meta-regression was undertaken. The result did not suggest a significant association under a random-effects meta-regression model (slope: 0.135; 95% CI: −0.504, 0.774; *p* = 0.679) (Fig. [4](#Fig4){ref-type="fig"}).Figure 4Meta-regression bubble plot of the association between mean changes in plasma Lp(a) concentrations following ezetimibe treatment with baseline plasma Lp(a) concentrations. The size of each circle is inversely proportional to the variance of change.

Publication bias {#Sec16}
----------------

Visual inspection of Begg's funnel plots showed an asymmetry in the meta-analyses of ezetimibe's effects on plasma Lp(a) concentrations. This asymmetry was corrected by imputing four potentially missing studies using "trim and fill" method, yielding a corrected effect size of −5.56 (95% CI: −10.50, −0.61) (Fig. [5](#Fig5){ref-type="fig"}). Consistently, Egger's regression test (*t = *3.38, df = 13, *p* = 0.005) did suggest the presence of publication bias. However, there was no sign of publication bias according to the Begg's rank correlation test (tau = −0.27, *z* = 1.39, *p* = 0.166).Figure 5Publication bias in the studies reporting the impact of ezetimibe treatment on plasma Lp(a) concentrations displayed as a Funnel plot. Open and closed circles represent reported studies and potentially missing studies imputed using "trim and fill" method.

Discussion {#Sec17}
==========

In this meta-analysis of randomized placebo-controlled clinical trials, ezetimibe therapy was not related to a significant reduction of plasma Lp(a) levels. This result was robust in the sensitivity analysis and was confirmed both when ezetimibe was used as monotherapy and in combination with a statin. In a previous meta-analysis, ezetimibe monotherapy was found to cause a significant but small and not clinically relevant reduction (7%) in plasma Lp(a) levels^[@CR49]^. The present meta-analysis provides a more robust confirmation on the lack of any Lp(a)-lowering effect of ezetimibe compared with referenced meta-analysis because of including a larger number of randomized controlled trials (*n* = 10 *vs*. 7). Moreover, in addition to the impact of monotherapy, this meta-analysis also evaluated the impact of the combination of ezetimibe and statins (*vs*. statin monotherapy) on plasma Lp(a) levels that has not been the subject of any prior meta-analysis.

Lp(a) is associated with acute coronary syndrome^[@CR13]^ and increased levels are found commonly in patients with premature coronary heart disease^[@CR14]^. Other studies including Lp(a) in a predictive model for cardiovascular prevention have suggested that the inclusion of Lp(a) in the models does increase their predictive value^[@CR50]--[@CR53]^. However, whilst Lp(a) elevation is associated with cardiovascular disease it is still unclear if there is a benefit in therapeutically targeting its reduction specifically. Although no specific therapy for lowering Lp(a) is as yet approved, the body of evidence supports the reducing effects by lipoprotein apheresis^[@CR54]^, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors^[@CR55]^, estrogen mimics and selective estrogen receptor modulators^[@CR56]--[@CR58]^, nicotinic acid^[@CR59]^ and some nutraceuticals^[@CR60]--[@CR63]^. Moreover, selective apo(a) antisense therapy has shown promising lowering effects in patients with elevated Lp(a) in phase II trials^[@CR64]^. With this background, an additional pharmacological tool for Lp(a)-lowering would be desirable.

Ezetimibe has a modest LDL-C-lowering efficacy that has been associated with a significant improvement of cardiovascular prognosis in the IMPROVE-IT trial^[@CR4]^. Given the reduction in plasma LDL-C levels with ezetimibe and the similarity in the lipid composition between Lp(a) and LDL particles^[@CR2],[@CR3]^, it might be hypothesized that ezetimibe would have also an impact on plasma Lp(a) levels. However, this meta-analysis collecting the inconsistent results of 10 randomized placebo-controlled trials was convincing that this is not the case, despite few studies reported a beneficial effect of ezetimibe on plasma Lp(a) levels^[@CR3],[@CR42],[@CR45],[@CR47]^. Clear reasons explaining the divergent results of the included trials did not emerge from the analytical comparison of each of them; however, we cannot rule out the hypothesis that untested or unreported data might have contributed to such an inconsistency. Thus, for instance, whether baseline BMI might have affected the Lp(a)-lowering efficacy of ezetimibe cannot be excluded; accordingly, in 3^[@CR3],[@CR42],[@CR45],[@CR47]^ out of 4 trials^[@CR3],[@CR42],[@CR45],[@CR47]^ reporting a significant impact of ezetimibe on Lp(a), average BMI was almost 29, whereas it was 26 in the only 2 trials^[@CR40],[@CR48]^ reporting the baseline BMI value of the study participants and which also showed a neutral effect of ezetimibe on Lp(a). Hence, further trials with complete reporting of the baseline characteristics of the study subjects are warranted.

This meta-analysis has a number of limitations. Firstly, effects of ezetimibe therapy on Lp(a) were not the primary aim of the clinical trials and the studies were not powered for this. Secondly, there were only 10 trials available to be analysed giving a modest though robust number of subjects to undertake the analysis. Thirdly, the longest duration of the trials exploring the Lp(a)-lowering effect of ezetimibe was 12 weeks, which might be too short to allow a greater impact on plasma Lp(a) levels. Finally, given the skewed distribution of Lp(a) values in the population, further clarification would benefit from pooled analyses of individual patient data.

Conclusion {#Sec18}
==========

The results of this meta-analysis suggest that ezetimibe treatment does not reduce plasma lipoprotein(a) levels and therefore Lp(a) reduction does not contribute to its therapeutic effect in cardiovascular prevention.
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